Silo Pharma, Inc.

NasdaqCM SILO

Silo Pharma, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -371.65%

Silo Pharma, Inc. Gross Profit Margin is -371.65% for the Trailing 12 Months (TTM) ending September 30, 2024, a -504.40% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Silo Pharma, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 91.90%, a 0.00% change year over year.
Silo Pharma, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 91.90%, a 332.65% change year over year.
Silo Pharma, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -39.50%, a -2,623.72% change year over year.
Silo Pharma, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was 1.57%.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqCM: SILO

Silo Pharma, Inc.

CEO	Mr. Eric Weisblum
IPO Date	Jan. 8, 2021
Location	United States
Headquarters	677 N. Washington Boulevard
Employees	3
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

Key trends

Past 5 years